Comment on "Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials".
- DOI
- 10.1016/j.ijcrp.2026.200694
- Published
- 2026-09-09
- Container
- Int J Cardiol Cardiovasc Risk Prev
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ijcrp.2026.200694,
title = {Comment on "Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials".},
author = {Gupta V and Ratnakar PJ and Shridevi K and Gaurav and Paul JR.},
year = {2026},
journal = {Int J Cardiol Cardiovasc Risk Prev},
doi = {10.1016/j.ijcrp.2026.200694},
url = {https://doi.org/10.1016/j.ijcrp.2026.200694}
}RIS
TY - JOUR TI - Comment on "Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials". AU - Gupta V AU - Ratnakar PJ AU - Shridevi K AU - Gaurav AU - Paul JR. PY - 2026 JO - Int J Cardiol Cardiovasc Risk Prev DO - 10.1016/j.ijcrp.2026.200694 UR - https://doi.org/10.1016/j.ijcrp.2026.200694 ER -
APA
V, G., PJ, R., K, S., Gaurav, & JR., P. (2026). Comment on "Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials".. Int J Cardiol Cardiovasc Risk Prev. https://doi.org/10.1016/j.ijcrp.2026.200694
Source records
- europe-pmc · retrieved 2026-09-25T15:20:16.042Z
- doaj · retrieved 2026-09-25T15:20:16.024Z